LeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should Know
Key Points
An executive of LeMaitre Vascular reported selling 2,625 shares of the company for $285,000 on March 11, 2026.
The sale represented 28.22% of Kamke's direct common stock holdings, reducing the position to 6,677 shares.
The transaction involved only direct holdings; no indirect entities participated, and the shares sold were converted from options immediately prior to sale.
- 10 stocks we like better than LeMaitre Vascular ›
Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, reported the exercise and immediate sale of 2,625 shares of common stock for a transaction value of approximately $285,000 on March 11, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 2,625 |
| Transaction value | ~$285,000 |
| Post-transaction shares (direct) | 6,677 |
| Post-transaction value (direct ownership) | ~$722,000 |
Transaction value based on SEC Form 4 weighted average purchase price ($108.50); post-transaction value based on March 11, 2026 market close price.
Key questions
- What is the derivative context of this transaction?
This filing reflects the exercise of 2,625 fully vested stock options, which were immediately converted and sold as common stock, aligning with standard liquidity events for equity compensation. - How did the transaction affect Kamke's ownership and potential future equity position?
After the sale, Kamke's direct common stock holdings decreased to 6,677 shares. - What proportion of Kamke's holdings was involved in this sale, and how does this compare to his recent trading pattern?
The transaction represented 28.22% of his pre-sale direct common stock holdings, matching the median percentage of holdings traded per sale in his recent activity since December 2024. - Were any indirect holdings or related entities involved in this transaction?
No indirect ownership entities participated; the entire transaction was executed in Kamke's direct account, and all shares transacted originated from option exercises.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $249.6 million |
| Net income (TTM) | $57.7 million |
| Dividend yield | 0.9% |
| 1-year price change | 30% |
Company snapshot
- LeMaitre Vascular offers a portfolio of medical devices and implants for the treatment of peripheral vascular disease, including angioscopes, embolectomy and thrombectomy catheters, carotid shunts, vascular grafts, and closure systems.
- The company generates revenue primarily through the direct sale and distribution of its proprietary vascular devices and surgical implants to hospitals and surgical centers.
- Key customers include vascular surgeons, interventionalists, and healthcare institutions specializing in vascular and cardiovascular procedures worldwide.
LeMaitre Vascular is a specialized medical device manufacturer focused on innovative solutions for vascular surgery and intervention. Its strategy emphasizes a diverse product portfolio and direct sales channels to drive growth in the global peripheral vascular market. The company's competitive edge stems from proprietary technologies and a targeted customer base within the healthcare sector.
What this transaction means for investors
This sale seems more like a typical option-driven liquidity event than a red flag for underlying fundamentals, especially considering the stock's recent strong performance and the nature of exercise-and-sell transactions. Still, the Form 4 doesn’t make note of any trading plan associated with this move, and it does come after a strong post-earnings surge.
Why the rise? LeMaitre reported that fourth-quarter sales increased 16% to $64.5 million and operating income soared 47% to $18.8 million, driven by strong pricing and manufacturing efficiencies. Meanwhile, full-year revenue totaled nearly $250 million, with earnings per share hitting $2.52, and the company gave better than expected guidance, including about $280 million in projected full-year sales for 2026. The company is also demonstrating confidence by raising its dividend by 25% and initiating a $100 million buyback program.
For long-term investors, insider selling related to options is less concerning than the company's execution. And with shares up about 30% over the past year, this rise seems closely linked to improved margins and consistent demand. The main risk now lies in potential valuation creep if growth slows, but operationally, the outlook remains strong.
Should you buy stock in LeMaitre Vascular right now?
Before you buy stock in LeMaitre Vascular, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and LeMaitre Vascular wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $503,268!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,049,793!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 27, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends LeMaitre Vascular. The Motley Fool has a disclosure policy.
Recommended Articles
